Stefan K. Barta, Jeannette Y. Lee, Lawrence D. Kaplan, Ariela Noy and Joseph A. Sparano Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma Cancer 118
Version of Record online: 16 DEC 2011 | DOI: 10.1002/cncr.26723
Clinical outcomes improve for patients with human immunodeficiency virus-associated lymphoma who receive concurrent rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin compared with patients who receive rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone when the analyses are adjusted for other covariates in a pooled analysis that includes 2 consecutive clinical trials. In addition, treatment-associated deaths occur significantly more often in patients who have baseline CD4 counts <50/μL irrespective of therapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field